Rallybio (RLYB) Competitors $0.70 +0.07 (+10.61%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$0.70 0.00 (0.00%) As of 03/27/2025 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RLYB vs. BMEA, BDTX, JAGX, PLRX, VTYX, ARTV, CRBU, IFRX, ATOS, and ORMPShould you be buying Rallybio stock or one of its competitors? The main competitors of Rallybio include Biomea Fusion (BMEA), Black Diamond Therapeutics (BDTX), Jaguar Health (JAGX), Pliant Therapeutics (PLRX), Ventyx Biosciences (VTYX), Artiva Biotherapeutics (ARTV), Caribou Biosciences (CRBU), InflaRx (IFRX), Atossa Therapeutics (ATOS), and Oramed Pharmaceuticals (ORMP). These companies are all part of the "pharmaceutical products" industry. Rallybio vs. Biomea Fusion Black Diamond Therapeutics Jaguar Health Pliant Therapeutics Ventyx Biosciences Artiva Biotherapeutics Caribou Biosciences InflaRx Atossa Therapeutics Oramed Pharmaceuticals Biomea Fusion (NASDAQ:BMEA) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability. Do insiders and institutionals hold more shares of BMEA or RLYB? 96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 90.3% of Rallybio shares are held by institutional investors. 27.6% of Biomea Fusion shares are held by company insiders. Comparatively, 7.4% of Rallybio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk and volatility, BMEA or RLYB? Biomea Fusion has a beta of -0.26, indicating that its stock price is 126% less volatile than the S&P 500. Comparatively, Rallybio has a beta of -1.45, indicating that its stock price is 245% less volatile than the S&P 500. Do analysts prefer BMEA or RLYB? Biomea Fusion presently has a consensus target price of $24.64, indicating a potential upside of 889.41%. Rallybio has a consensus target price of $9.75, indicating a potential upside of 1,282.98%. Given Rallybio's higher probable upside, analysts plainly believe Rallybio is more favorable than Biomea Fusion.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomea Fusion 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00Rallybio 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the MarketBeat Community prefer BMEA or RLYB? Biomea Fusion received 16 more outperform votes than Rallybio when rated by MarketBeat users. However, 78.57% of users gave Rallybio an outperform vote while only 68.97% of users gave Biomea Fusion an outperform vote. CompanyUnderperformOutperformBiomea FusionOutperform Votes6068.97% Underperform Votes2731.03% RallybioOutperform Votes4478.57% Underperform Votes1221.43% Does the media favor BMEA or RLYB? In the previous week, Biomea Fusion had 13 more articles in the media than Rallybio. MarketBeat recorded 16 mentions for Biomea Fusion and 3 mentions for Rallybio. Rallybio's average media sentiment score of 0.97 beat Biomea Fusion's score of 0.35 indicating that Rallybio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomea Fusion 1 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Rallybio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is BMEA or RLYB more profitable? Rallybio's return on equity of -77.39% beat Biomea Fusion's return on equity.Company Net Margins Return on Equity Return on Assets Biomea FusionN/A -118.90% -93.66% Rallybio N/A -77.39%-69.33% Which has better earnings and valuation, BMEA or RLYB? Rallybio has higher revenue and earnings than Biomea Fusion. Biomea Fusion is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiomea FusionN/AN/A-$117.25M-$4.01-0.62Rallybio$636K46.13-$74.56M-$1.35-0.52 SummaryRallybio beats Biomea Fusion on 9 of the 17 factors compared between the two stocks. Remove Ads Get Rallybio News Delivered to You Automatically Sign up to receive the latest news and ratings for RLYB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLYB vs. The Competition Export to ExcelMetricRallybioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.34M$6.91B$5.64B$8.06BDividend YieldN/A2.73%4.56%4.02%P/E Ratio-0.447.2023.1319.03Price / Sales46.13226.00383.8993.17Price / CashN/A65.6738.1634.64Price / Book0.256.476.944.33Net Income-$74.56M$141.90M$3.20B$247.06M7 Day Performance0.71%-3.05%-2.32%-0.53%1 Month Performance-4.73%-4.63%3.07%-3.74%1 Year Performance-55.66%-8.61%11.16%1.72% Rallybio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLYBRallybio2.5256 of 5 stars$0.71+10.6%$9.75+1,283.0%-55.7%$29.34M$636,000.00-0.4440BMEABiomea Fusion3.1304 of 5 stars$2.79-2.8%$29.18+945.9%-83.8%$101.11MN/A-0.7050BDTXBlack Diamond Therapeutics3.236 of 5 stars$1.68-5.6%$14.60+769.0%-65.9%$100.86MN/A-1.2690High Trading VolumeJAGXJaguar Health0.5858 of 5 stars$6.04+4.6%N/A-95.1%$99.07M$10.48M0.0050Analyst ForecastShort Interest ↓News CoverageHigh Trading VolumePLRXPliant Therapeutics4.3309 of 5 stars$1.59+2.6%$13.31+737.3%-89.6%$97.37M$1.58M-0.4890Short Interest ↑VTYXVentyx Biosciences2.2295 of 5 stars$1.36+3.0%$10.00+635.3%-78.8%$96.74MN/A-0.5830Positive NewsARTVArtiva BiotherapeuticsN/A$3.91-8.4%$21.00+437.1%N/A$94.97M$2.60M0.0081Analyst ForecastAnalyst RevisionNews CoverageCRBUCaribou Biosciences3.4178 of 5 stars$1.02-1.9%$10.33+913.1%-80.7%$94.87M$9.99M-0.62100Short Interest ↓IFRXInflaRx2.4438 of 5 stars$1.41+10.2%$8.00+467.4%-18.8%$94.66M$165,789.00-1.3160Analyst ForecastHigh Trading VolumeATOSAtossa Therapeutics1.4833 of 5 stars$0.75-0.5%$7.00+833.3%-61.8%$94.35MN/A-3.418Earnings ReportAnalyst ForecastNews CoverageGap UpORMPOramed Pharmaceuticals1.6767 of 5 stars$2.34+0.4%N/A-18.4%$94.33M$1.34M21.2710 Remove Ads Related Companies and Tools Related Companies Biomea Fusion Alternatives Black Diamond Therapeutics Alternatives Jaguar Health Alternatives Pliant Therapeutics Alternatives Ventyx Biosciences Alternatives Artiva Biotherapeutics Alternatives Caribou Biosciences Alternatives InflaRx Alternatives Atossa Therapeutics Alternatives Oramed Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RLYB) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rallybio Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rallybio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.